- Home
- PAYO vs COGT Comparison
PAYO vs COGT Comparison
Compare PAYO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYO
- COGT
- Stock Information
- Founded
- PAYO 2005
- COGT 2014
- Country
- PAYO United States
- COGT United States
- Employees
- PAYO N/A
- COGT N/A
- Industry
- PAYO EDP Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- PAYO Technology
- COGT Health Care
- Exchange
- PAYO Nasdaq
- COGT Nasdaq
- Market Cap
- PAYO 2.1B
- COGT 2.3B
- IPO Year
- PAYO N/A
- COGT 2018
- Fundamental
- Price
- PAYO $5.25
- COGT $14.92
- Analyst Decision
- PAYO Strong Buy
- COGT Strong Buy
- Analyst Count
- PAYO 8
- COGT 12
- Target Price
- PAYO $10.06
- COGT $22.00
- AVG Volume (30 Days)
- PAYO 2.7M
- COGT 2.5M
- Earning Date
- PAYO 11-05-2025
- COGT 10-31-2025
- Dividend Yield
- PAYO N/A
- COGT N/A
- EPS Growth
- PAYO N/A
- COGT N/A
- EPS
- PAYO 0.18
- COGT N/A
- Revenue
- PAYO $1,039,820,000.00
- COGT N/A
- Revenue This Year
- PAYO $9.64
- COGT N/A
- Revenue Next Year
- PAYO $7.37
- COGT N/A
- P/E Ratio
- PAYO $29.58
- COGT N/A
- Revenue Growth
- PAYO 10.58
- COGT N/A
- 52 Week Low
- PAYO $4.92
- COGT $3.72
- 52 Week High
- PAYO $11.29
- COGT $17.15
- Technical
- Relative Strength Index (RSI)
- PAYO 28.70
- COGT 48.25
- Support Level
- PAYO $4.92
- COGT $13.79
- Resistance Level
- PAYO $5.87
- COGT $16.76
- Average True Range (ATR)
- PAYO 0.20
- COGT 0.95
- MACD
- PAYO -0.04
- COGT -0.25
- Stochastic Oscillator
- PAYO 25.56
- COGT 34.23
About PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.